MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318495 | Name: Pioglitazone HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pioglitazone Hydrochloride is a thiazolidinedione compound described to produce antiinflammatory and antiarteriosclerotic effects. Pioglitazone is demonstrated to prevent L-NAME-induced coronary inflammation and arteriosclerosis and to suppress increased TNF-α mRNA produced by aspirin-induced gastric mucosal injury. Pioglitazone Hydrochloride is an activator of PPAR γ.

Chemical Structure

Pioglitazone HCl
Pioglitazone HCl
CAS#112529-15-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 318495

Name: Pioglitazone HCl

CAS#: 112529-15-4 (HCl)

Chemical Formula: C19H21ClN2O3S

Exact Mass: 0.0000

Molecular Weight: 392.90

Elemental Analysis: C, 58.08; H, 5.39; Cl, 9.02; N, 7.13; O, 12.22; S, 8.16

Price and Availability

Size Price Availability Quantity
500mg USD 90.00 Ready to ship
1g USD 150.00 Ready to ship
2g USD 250.00 Ready to ship
5g USD 450.00 Ready to ship
10g USD 750.00 Ready to ship
20g USD 1,150.00 Ready to ship
50g USD 2,050.00 2 weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
112529-15-4 (HCl) 111025-46-8 (free base)
Synonym
Pioglitazone Hydrochloride; Pioglitazone HCl; Actos; U-72107A; AD 4833; AD-4833; pioglitazone; pioglitazone hydrochloride; U 72107A; U-72107A; U72,107A;
IUPAC/Chemical Name
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride
InChi Key
GHUUBYQTCDQWRA-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H
SMILES Code
CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3.Cl
Appearance
White to off-white solidw powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# CAS#111025-46-8 (Pioglitazone free base). CAS#112529-15-4 (Pioglitazone HCl)
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#TC60808
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
In vitro activity:
Rhodamine-phalloidin was used to detect the actin filaments of NP-MSCs. The results displayed that compression obviously broke the actin stress fibers and pioglitazone rescued the adverse outcomes caused by compression (Figure 3(a)). Subsequently, the release of LDH was detected. The results demonstrated that compression significantly enhanced the release of LDH compared with the control group. Pioglitazone significantly reversed the release of LDH induced by compression (Figure 3(b)). To further assess the protective effects of pioglitazone on compression-induced cytotoxicity in NP-MSCs, a calcein-AM/PI assay was used to quantify the numbers of live/dead cells under a fluorescence microscope. It was found that live cells (green fluorescence) were more in the pioglitazone groups while dead cells (red fluorescence) were more frequent in the compression groups (Figures 3(c)–3(e)). Those results demonstrated that pioglitazone protected against compression-induced cell cytotoxicity in NP-MSCs.). Reference: Oxid Med Cell Longev. 2019; 2019: 4764071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893265/
In vivo activity:
To determine if pioglitazone inhibited obesity associated periprostatic WAT inflammation, obese HF diet fed mice were either continued on HF diet alone or treated with HF diet containing two doses (0.006%, 0.06% w/w) of pioglitazone Fig. 1A). Interestingly, treatment with either dose of pioglitazone led to a marked increase in calorie consumption without causing significant weight gain (Figs. 1C and D). Notably, treatment with pioglitazone led to a dose-dependent decrease in periprostatic WAT inflammation (Fig. 1E). As shown in Fig. 2C, HF diet led to an increase in levels of MCP-1, an effect that was suppressed by 0.06% (w/w) pioglitazone. Similarly, periprostatic WAT inflammation was associated with increased levels of TNF-α and TGF-β; these changes were attenuated by treatment with 0.06% (w/w) pioglitazone (Figs. 2D and E). Mice were then either continued on HF or LF diets or treated with HF diet containing 0.06% (w/w) pioglitazone for 2, 4 or 9 weeks. Here, treatment with pioglitazone for 4 or 9 weeks caused hyperphagia (Fig. 3C) in the absence of inducing weight gain (Fig. 3B). Treatment with pioglitazone led to reduced number of CLS/cm2 in WAT after 4 and 9 weeks of treatment (Fig. 3D). Importantly, pioglitazone, an anti-diabetic drug, protected against HF diet-induced periprostatic WAT inflammation. Reference: Cancer Prev Res (Phila). 2018 Apr; 11(4): 215–226. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882568/
Solvent mg/mL mM comments
Solubility
DMSO 10.0 25.50
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 392.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Hu Y, Huang L, Shen M, Liu Y, Liu G, Wu Y, Ding F, Ma K, Wang W, Zhang Y, Shao Z, Cai X, Xiong L. Pioglitazone Protects Compression-Mediated Apoptosis in Nucleus Pulposus Mesenchymal Stem Cells by Suppressing Oxidative Stress. Oxid Med Cell Longev. 2019 Nov 22;2019:4764071. doi: 10.1155/2019/4764071. PMID: 31885796; PMCID: PMC6893265. 2. Shahid M, Kim M, Yeon A, Jin P, Kim WK, You S, Kim J. Pioglitazone Alters the Proteomes of Normal Bladder Epithelial Cells but Shows No Tumorigenic Effects. Int Neurourol J. 2020 Mar;24(1):29-40. doi: 10.5213/inj.1938186.093. Epub 2020 Mar 31. PMID: 32252184; PMCID: PMC7136443. 3. Hu Y, Huang L, Shen M, Liu Y, Liu G, Wu Y, Ding F, Ma K, Wang W, Zhang Y, Shao Z, Cai X, Xiong L. Pioglitazone Protects Compression-Mediated Apoptosis in Nucleus Pulposus Mesenchymal Stem Cells by Suppressing Oxidative Stress. Oxid Med Cell Longev. 2019 Nov 22;2019:4764071. doi: 10.1155/2019/4764071. PMID: 31885796; PMCID: PMC6893265 4. Shahid M, Kim M, Yeon A, Jin P, Kim WK, You S, Kim J. Pioglitazone Alters the Proteomes of Normal Bladder Epithelial Cells but Shows No Tumorigenic Effects. Int Neurourol J. 2020 Mar;24(1):29-40. doi: 10.5213/inj.1938186.093. Epub 2020 Mar 31. PMID: 32252184; PMCID: PMC7136443.
In vitro protocol:
1. Hu Y, Huang L, Shen M, Liu Y, Liu G, Wu Y, Ding F, Ma K, Wang W, Zhang Y, Shao Z, Cai X, Xiong L. Pioglitazone Protects Compression-Mediated Apoptosis in Nucleus Pulposus Mesenchymal Stem Cells by Suppressing Oxidative Stress. Oxid Med Cell Longev. 2019 Nov 22;2019:4764071. doi: 10.1155/2019/4764071. PMID: 31885796; PMCID: PMC6893265. 2. Shahid M, Kim M, Yeon A, Jin P, Kim WK, You S, Kim J. Pioglitazone Alters the Proteomes of Normal Bladder Epithelial Cells but Shows No Tumorigenic Effects. Int Neurourol J. 2020 Mar;24(1):29-40. doi: 10.5213/inj.1938186.093. Epub 2020 Mar 31. PMID: 32252184; PMCID: PMC7136443.
In vivo protocol:
1. Miyazawa M, Subbaramaiah K, Bhardwaj P, Zhou XK, Wang H, Falcone DJ, Giri DD, Dannenberg AJ. Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. Cancer Prev Res (Phila). 2018 Apr;11(4):215-226. doi: 10.1158/1940-6207.CAPR-17-0296. Epub 2017 Dec 8. PMID: 29222347; PMCID: PMC5882568. 2. van der Veen JN, Lingrell S, Gao X, Quiroga AD, Takawale A, Armstrong EA, Yager JY, Kassiri Z, Lehner R, Vance DE, Jacobs RL. Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2016 Apr 1;310(7):G526-38. doi: 10.1152/ajpgi.00243.2015. Epub 2016 Jan 21. PMID: 26797396.
1: Akabari AH, Gajiwala H, Patel SK, Surati J, Solanki D, Shah KV, Patel TJ, Patel SP. Stability-Indicating TLC-Densitometric and HPLC Methods for Simultaneous Determination of Teneligliptin and Pioglitazone in Pharmaceutical Dosage Forms with Eco-Friendly Assessment. J Chromatogr Sci. 2024 Jun 5:bmae038. doi: 10.1093/chromsci/bmae038. Epub ahead of print. PMID: 38836346. 2: Zhang D, Wang W, Zhao H, Wang S, Yu M, Zhang D, Liu W, Xie Q, Chen D. Structural Identification of Impurities in Pioglitazone Hydrochloride Preparations by 2D-UHPLC-Q-Exactive Orbitrap HRMS and Their Toxicity Prediction. Int J Anal Chem. 2023 Oct 17;2023:2096521. doi: 10.1155/2023/2096521. PMID: 37881366; PMCID: PMC10597724. 3: Chunu JT, Ozalp Y, Jiwa N, Erginer YO, Mesut B. Compressibility behavior of pioglitazone hydrochloride in mannitol-based formulations: An investigation using compaction simulator and QbD approach. Pak J Pharm Sci. 2023 Sep;36(5):1515-1526. PMID: 37869928. 4: Pouya FD, Salehi R, Rasmi Y, Kheradmand F, Fathi-Azarbayjani A. Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers. Life Sci. 2023 Nov 1;332:122083. doi: 10.1016/j.lfs.2023.122083. Epub 2023 Sep 17. PMID: 37717622. 5: Van Duong T, Diab S, Hodnett NS, Taylor LS. Kinetic Barriers to Disproportionation of Salts of Weakly Basic Drugs. Mol Pharm. 2023 Aug 7;20(8):3886-3894. doi: 10.1021/acs.molpharmaceut.2c01034. Epub 2023 Jul 26. PMID: 37494545. 6: Tong TT, Wang Y, Li KW, Zhang LD, Wu XQ, Wang JL, Li CL, Zhang GQ, Zhang JY, Han W. [Effect of Tongdu Tiaoshen electroacupuncture pretreatment on PPARγ-mediated pyroptosis of cerebral cortex in rats with cerebral ischemia reperfusion injury]. Zhongguo Zhen Jiu. 2023 Jul 12;43(7):783-92. Chinese. doi: 10.13703/j.0255-2930.20221010-k0004. PMID: 37429658. 7: Villeda-Villegas M, Páez-Franco JC, Coyote-Dotor G, Núñez-Pineda A, Dorazco- González A, Fuentes-Noriega I, Rubio-Carrasco K, Toledo Jaldín HP, Morales- Morales D, Germán-Acacio JM. Diversity of Solid Forms Promoted by Ball Milling: Characterization and Intrinsic Dissolution Studies of Pioglitazone Hydrochloride and Fluvastatin Sodium Drug-Drug Systems. Pharmaceuticals (Basel). 2023 May 24;16(6):781. doi: 10.3390/ph16060781. PMID: 37375729; PMCID: PMC10303448. 8: Jianfang F, Wanxia X, Xiling G, Jing X, Wenjuan Y, Jianrong L, Qingzhen H, Kaiyan M, Jingxuan L, Taixiong C, Qian X, Mengying L, Jie M, Qiuhe J. Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study. J Diabetes Res. 2023 Jun 1;2023:2044090. doi: 10.1155/2023/2044090. PMID: 37305429; PMCID: PMC10250100. 9: Fernandes S, Borges A, Gomes IB, Sousa SF, Simões M. Curcumin and 10-undecenoic acid as natural quorum sensing inhibitors of LuxS/AI-2 of Bacillus subtilis and LasI/LasR of Pseudomonas aeruginosa. Food Res Int. 2023 Mar;165:112519. doi: 10.1016/j.foodres.2023.112519. Epub 2023 Jan 24. PMID: 36869520. 10: Muñoz Tecocoatzi MF, Páez-Franco JC, Rubio-Carrasco K, Núñez-Pineda A, Dorazco-González A, Fuentes-Noriega I, Vilchis-Néstor AR, Olvera LI, Morales- Morales D, Germán-Acacio JM. Ball-Milling Preparation of the Drug-Drug Solid Form of Pioglitazone-Rosuvastatin at Different Molar Ratios: Characterization and Intrinsic Dissolution Rates Evaluation. Pharmaceutics. 2023 Feb 13;15(2):630. doi: 10.3390/pharmaceutics15020630. PMID: 36839951; PMCID: PMC9959797. 11: Rehman HU, Kakar AUR, Yaqoob M, Asghar M, Saeed Ahmed S, Nisa KU. Determination of pioglitazone hydrochloride by flow injection chemiluminescence tris(2,2'-bipyridyl)ruthenium(II)-silver(III) complex system. Luminescence. 2023 Feb;38(2):99-108. doi: 10.1002/bio.4420. Epub 2022 Dec 27. PMID: 36494159. 12: Jia W, Wang C, Zheng J, Li Y, Yang C, Wan QL, Shen J. Pioglitazone Hydrochloride Extends the Lifespan of Caenorhabditis elegans by Activating DAF-16/FOXO- and SKN-1/NRF2-Related Signaling Pathways. Oxid Med Cell Longev. 2022 May 29;2022:8496063. doi: 10.1155/2022/8496063. PMID: 35677109; PMCID: PMC9168093. 13: Teaima M, Hababeh S, Khanfar M, Alanazi F, Alshora D, El-Nabrawi M. Design and Optimization of Pioglitazone Hydrochloride Self-Nanoemulsifying Drug Delivery System (SNEDDS) Incorporated into an Orally Disintegrating Tablet. Pharmaceutics. 2022 Feb 16;14(2):425. doi: 10.3390/pharmaceutics14020425. PMID: 35214157; PMCID: PMC8880587. 14: Prajapati PB, Mistry KY, Shah SA. DoE-Based Analytical Failure Modes Critical Effect Analysis (AFMCEA) to a Multipurpose-RP-HPLC Method for the Estimation of Multiple FDC Products of Metformin Hydrochloride Using an Analytical Quality by Design Approach. J AOAC Int. 2022 Jun 29;105(4):986-998. doi: 10.1093/jaoacint/qsac025. PMID: 35176154. 15: Ghoniem NS, Hussien EM, Atta MY, Hegazy MA. Spectrophotometric methods for determination of glimepiride and pioglitazone hydrochloride mixture and application in their pharmaceutical formulation. Spectrochim Acta A Mol Biomol Spectrosc. 2022 Apr 5;270:120745. doi: 10.1016/j.saa.2021.120745. Epub 2021 Dec 14. PMID: 34972054. 16: Ding Y, Cheng Y, Hao B, Zhu L, Zhang N, Zhao B, Tian Y. Metal-organic framework modified by silver nanoparticles for SERS-based determination of sildenafil and pioglitazone hydrochloride. Mikrochim Acta. 2021 Sep 23;188(10):351. doi: 10.1007/s00604-021-05008-4. PMID: 34554332. 17: Teng Y, Zhao Z, Tasnim F, Huang X, Yu H. A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids. Biomaterials. 2021 Aug;275:120904. doi: 10.1016/j.biomaterials.2021.120904. Epub 2021 Jun 1. PMID: 34119888. 18: Zhang F, Jin C, Wang X, Yan H, Tan H, Gao C. Dietary supplementation with pioglitazone hydrochloride and l-carnosine improves the growth performance, muscle fatty acid profiles and shelf life of yellow-feathered broiler chickens. Anim Nutr. 2021 Mar;7(1):168-175. doi: 10.1016/j.aninu.2020.05.011. Epub 2020 Dec 31. PMID: 33997345; PMCID: PMC8110847. 19: Umemura M, Narikawa M, Tanaka R, Nemoto H, Nakakaji R, Nagasako A, Ishikawa Y. [Doxorubicin directly induced fibrotic change of cardiac fibroblasts]. Nihon Yakurigaku Zasshi. 2021;156(3):146-151. Japanese. doi: 10.1254/fpj.20101. PMID: 33952842. 20: Kumar A, Srivastava SK, Srivastava M, Prakash R. Electrochemical sensing of pioglitazone hydrochloride on N-doped r-GO modified commercial electrodes. Analyst. 2021 Jun 7;146(11):3578-3588. doi: 10.1039/d1an00224d. Epub 2021 Apr 29. PMID: 33913938.

View History

Pipebuzone

Pipebuzone